Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy

od Guiu, S., Mouret Reynier, M. A., Toure, M., Coudert, B.
Izdano 2013

Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells.

od Chauffert, B., Rey, D., Coudert, B., Dumas, M., Martin, F.
Izdano 1987

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

od Ladoire, S, Arnould, L, Mignot, G, Apetoh, L, Rébé, C, Martin, F, Fumoleau, P, Coudert, B, Ghiringhelli, F
Izdano 2011

Nilutamide pneumonitis: a report on eight patients.

od Pfitzenmeyer, P, Foucher, P, Piard, F, Coudert, B, Braud, M L, Gabez, P, Lacroix, S, Mabille, J P, Camus, P
Izdano 1992

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma

od Végran, F, Boidot, R, Coudert, B, Fumoleau, P, Arnould, L, Garnier, J, Causeret, S, Fraise, J, Dembélé, D, Lizard-Nacol, S
Izdano 2009

Impairment of diastolic function during short-term anthracycline chemotherapy.

od Cottin, Y., Touzery, C., Coudert, B., Gilles, A., Walker, P., Massing, J. L., Toubeau, M., Riedinger-Berriolo, A., Caillot, D., Louis, P.
Izdano 1995

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

od Guiu, S, Gauthier, M, Coudert, B, Bonnetain, F, Favier, L, Ladoire, S, Tixier, H, Guiu, B, Penault-Llorca, F, Ettore, F, Fumoleau, P, Arnould, L
Izdano 2010

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

od Arnould, L, Gelly, M, Penault-Llorca, F, Benoit, L, Bonnetain, F, Migeon, C, Cabaret, V, Fermeaux, V, Bertheau, P, Garnier, J, Jeannin, J-F, Coudert, B
Izdano 2006

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

od Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Izdano 2007

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

od Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Izdano 2008

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)

od Dano, D., Lardy-Cleaud, A., Monneur, A., Quenel-Tueux, N., Levy, C., Mouret-Reynier, M.-A., Coudert, B., Mailliez, A., Ferrero, J.-M., Guiu, S., Campone, M., de La Motte Rouge, T., Petit, T., Pistilli, B., Dalenc, F., Simon, G., Lerebours, F., Chabaud, S., Bertucci, F., Gonçalves, A.
Izdano u ESMO Open (2021)